Toshiyuki Kitai1,2, Yutaka Yonemura3. 1. Department of Surgery, Kishiwada City Hospital, uhara-cho, Kishiwada, Osaka, 596-8501, Japan. kitait@kcn.jp. 2. Department of Surgery, Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokushukai Hospital, 4-27-1 Kamoricho, Kishiwada, Osaka, 5960042, Japan. kitait@kcn.jp. 3. Department of Surgery, Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokushukai Hospital, 4-27-1 Kamoricho, Kishiwada, Osaka, 5960042, Japan.
Abstract
BACKGROUND: Appendiceal mucinous neoplasm (AMN) is a rare tumor that may be successfully treated by appendectomy. However, some patients develop recurrence as pseudomyxoma peritonei. The present study investigated the recurrence rate after radial resection for AMN. METHODS: A survey on AMN was sent to 171 institutions, and 286 cases were analyzed. The risk of recurrence was assessed according to clinical parameters. Recurrence rates were compared with data from the literature. RESULTS: There were 250 cases in the low-grade group and 36 in the high-grade group, with perforation being detected in 50 cases. After a median follow-up period of 30 months, recurrence was detected in 17 cases, including 12 with high-grade histology and 10 with perforation. Two patients with low-grade histology and no perforation developed recurrence. Independent prognostic factors for recurrence were high-grade histology (p = 0.0001, RR = 8.56) and perforation (p = 0.0168, RR = 3.45). Four groups were classified by histology and perforation: group A: high-grade, perforation ( +), group B: high-grade, perforation (-), group C: low-grade, perforation ( +), group D: low-grade, perforation (-). Five-year recurrence rates in groups A, B, C, and D were 46.7, 25.9, 13.3, and 1.5%, respectively. All cases of recurrence were detected within 3 years, except for two in group B. CONCLUSIONS: Recurrence in cases with low-grade histology and no perforation was rare; however, a postoperative survey for at least 3 years is required. In contrast, cases with high-grade histology or perforation need to be monitored using a similar approach to colon cancer. Prophylactic CRS + HIPEC may be considered.
BACKGROUND: Appendiceal mucinous neoplasm (AMN) is a rare tumor that may be successfully treated by appendectomy. However, some patients develop recurrence as pseudomyxoma peritonei. The present study investigated the recurrence rate after radial resection for AMN. METHODS: A survey on AMN was sent to 171 institutions, and 286 cases were analyzed. The risk of recurrence was assessed according to clinical parameters. Recurrence rates were compared with data from the literature. RESULTS: There were 250 cases in the low-grade group and 36 in the high-grade group, with perforation being detected in 50 cases. After a median follow-up period of 30 months, recurrence was detected in 17 cases, including 12 with high-grade histology and 10 with perforation. Two patients with low-grade histology and no perforation developed recurrence. Independent prognostic factors for recurrence were high-grade histology (p = 0.0001, RR = 8.56) and perforation (p = 0.0168, RR = 3.45). Four groups were classified by histology and perforation: group A: high-grade, perforation ( +), group B: high-grade, perforation (-), group C: low-grade, perforation ( +), group D: low-grade, perforation (-). Five-year recurrence rates in groups A, B, C, and D were 46.7, 25.9, 13.3, and 1.5%, respectively. All cases of recurrence were detected within 3 years, except for two in group B. CONCLUSIONS: Recurrence in cases with low-grade histology and no perforation was rare; however, a postoperative survey for at least 3 years is required. In contrast, cases with high-grade histology or perforation need to be monitored using a similar approach to colon cancer. Prophylactic CRS + HIPEC may be considered.
Authors: Boateng Kubi; Richard Nudotor; Nadege Fackche; Wasay Nizam; Jordan M Cloyd; Travis E Grotz; Keith F Fournier; Sean P Dineen; Benjamin D Powers; Jula Veerapong; Joel M Baumgartner; Callisia N Clarke; Sameer H Patel; Laura A Lambert; Daniel E Abbott; Kara A Vande Walle; Mustafa Raoof; Byrne Lee; Shishir K Maithel; Charles A Staley; Fabian M Johnston; Jonathan B Greer Journal: Ann Surg Oncol Date: 2021-01-28 Impact factor: 5.344
Authors: Charles Honoré; Francesco Caruso; Peggy Dartigues; Léonor Benhaim; Mircea Chirica; Diane Goéré; Dominique Elias Journal: Anticancer Res Date: 2015-09 Impact factor: 2.480
Authors: Jason M Foster; Richard L Sleightholm; Steve Wahlmeier; Brian Loggie; Poonam Sharma; Asish Patel Journal: World J Surg Oncol Date: 2016-09-13 Impact factor: 2.754